A Phase II, Multi-center, Open-label, Randomized Study Evaluating the Anti-tumor Activity of SB-485232, rhIL-18, Administered as Five Daily Intravenous Infusions Every 28 Days in Subjects With Previously Untreated Metastatic Melanoma
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate of tumor.
GSK Clinical Trials, MD
Study Director
GlaxoSmithKline
United States: Food and Drug Administration
SB-485232/006
NCT00107718
November 2004
May 2006
Name | Location |
---|---|
GSK Investigational Site | Bakersfield, California 93309 |
GSK Investigational Site | Gainesville, Florida 32610 |
GSK Investigational Site | Indianapolis, Indiana 46260 |
GSK Investigational Site | Akron, Ohio 44304 |
GSK Investigational Site | Park Ridge, Illinois 60068 |
GSK Investigational Site | Baltimore, Maryland 21201 |
GSK Investigational Site | Pittsburgh, Pennsylvania 15213 |
GSK Investigational Site | New York, New York 10021 |
GSK Investigational Site | Hartford, Connecticut 06106 |